Abstract library

523 results for "irritable bowel syndrome".
#121 Serotonin synthesis inhibitors: a novel approach for managing gastrointestinal symptoms in carcinoid syndrome
Introduction: Carcinoid syndrome (CS) occurs when metastatic carcinoid tumors secrete large amounts of serotonin (5-HT) and other bioactive substances into systemic circulation, causing a variety of symptoms, including GI symptoms such as profound diarrhea. Reduction in 5-HT production by the tumor would be expected to improve symptoms in patients with CS.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jay L Mitchell
#1331 The Symptoms Experienced by Small Bowel and Pancreatic NET Patients Prior to Diagnosis Do Not Meet the Criteria for a Functional Diarrhoea (IBS-D) Diagnosis
Introduction: Patients with neuroendocrine tumours (NETs) complain of symptoms that may be mistaken for irritable bowel syndrome (IBS). There is no clear data if these symptoms overlap with those of IBS or if differentiating symptoms co-exist.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Ron Basuroy
#1363 Efficacy of Lutetium-177 DOTA Octreotate Peptide Receptor Radionuclide Therapy in Patients with Advanced Neuroendocrine Tumours and Carcinoid Syndrome Refractory to Somatostatin Analogues
Introduction: Somatostatin Analogues (SSAs) are considered the gold standard treatment in Neuroendocrine Tumours (NETs) and carcinoid syndrome.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Apostolos Koffas
#2262 Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome
Introduction: Telotristat ethyl (TE) is a treatment for carcinoid syndrome (CS) diarrhea used in combination with somatostatin analog (SSA) therapy. In the Phase 3, randomized, placebo-controlled, double-blind TELESTAR and TELECAST studies, CS patients received TE at 250 mg 3 times per day (tid), 500 mg tid, or placebo tid in addition to SSAs.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - others, not specified
Presenting Author: Dr Emma Leah
#3042 The Use of Total Parenteral Nutrition in a Series of Patients with Neuroendocrine Tumours in United Kingdom and the Netherlands
Introduction: There are controversies about the use of total parental nutrition (TPN) in patients with cancer. Currently data regarding TPN use in patients with neuroendocrine tumours (NETs) are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Dominique Clement
#255 The Carcinoid Syndrome Caused by Retroperitoneal Carcinoid Tumors
Introduction: The carcinoid syndrome is caused by increased levels of serotonin and is mostly seen in cases of carcinoid tumor in the small bowel and liver metastases, as there is a very high first pass effect.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Benedicte V Wilson
Authors: Wilson B, Nielsen H O, ...
#2061 Midgut Carcinoids Presenting as Subacute Intestinal Obstruction. A Case Report of Territory Care Hospital.
Introduction: Midgut carcinoids are well differentiated neuroendocrine tumors possessing secretary properties releasing various peptides. Over the past few decades, there incidence has been increased. Since countries like Pakistan lack the diagnostic facilities, they are often misdiagnosed.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...
#2236 Carcinoid Syndrome Open Questions – Evaluations from a Real Life Setting
Introduction: Carcinoid syndrome (CS) is frequent in patients with neuroendocrine neoplasia of the small bowel and limits quality of life and may influence prognosis compared to patients with non-functional neuroendocrine neoplasia.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Robert Fijalkowski
#2840 A Real-World Study of Patients with Carcinoid Syndrome at King’s College Hospital on Long-Term Telotristat Therapy
Introduction: Telotristat ethyl is a tryptophan hydroxylase inhibitor that has been shown to be effective against symptoms of carcinoid syndrome refractory to standard somatostatin analogue therapy by directly inhibiting serotonin production. While clinical trials have established short-term efficacy of the drug, we report an exploratory real-world study of 15 patients with metastatic neuroendocrine tumours on long-term Telotristat (median duration=8 months).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Doctor Shweta Hota
Authors: Hota S, Cananea E, Martin W, Clement D, ...
#394 Efficacy of Telotristat Etiprate in Refractory Carcinoid Syndrome: Results of a Randomized, Placebo-controlled, Multicenter Study
Introduction: Diarrhea associated with carcinoid syndrome (CS) has been attributed to excess serotonin. Telotristat etiprate is an oral serotonin synthesis inhibitor that decreases peripheral serotonin production.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Matthew Kulke